0
Skip to Content
K2 Health Ventures
Approach
Team
Portfolio
News
Purpose
Contact
K2 Health Ventures
Approach
Team
Portfolio
News
Purpose
Contact
Approach
Team
Portfolio
News
Purpose
Contact

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

k2hv news
Apr 25
Written by MacDougall Creative
MacDougall Creative https://www.macbiocom.com
Previous
Previous

Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer
Next
Next

Harpoon Therapeutics Announces Closing of $25 Million Private Placement

If you would like to learn more about K2 HealthVentures, would like to suggest or submit an investment opportunity, or are interested in joining our team, please click here to email us.

Contact Us
Copyright© K2 HealthVentures™. All rights reserved.